search
Back to results

Phase I Multiple-Ascending Dose (Japan) (MAD)

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 1
Locations
Japan
Study Type
Interventional
Intervention
Dapagliflozin
placebo
Sponsored by
AstraZeneca
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

20 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Japanese male and female subjects
  • Ages 20 to 70 years old
  • Established diagnosis of T2DM
  • BMI < 32 kg/m2
  • Fasting glucose ≤ 240 mg/dL, while on antidiabetic diet alone
  • HbA1C 6.0 - 10.0%

Exclusion Criteria:

  • Symptomatic T2DM defined as polyuria and/or polydipsia within 2 months of enrollment
  • History of diabetic ketoacidosis or hyperosmolar nonketotic syndrome
  • History of incontinence or bladder dysfunction including nocturia

Sites / Locations

  • Local Institution

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

Arm 1

Arm 2

Arm 3

Arm 4

Arm Description

2.5 mg

10 mg

20 mg

Outcomes

Primary Outcome Measures

AEs, vital signs & physical exam
ECGs
Clinical labs
Urine safety markers

Secondary Outcome Measures

24 hr PK blood & urine samples
Serum glucose, serum insulin, serum c-peptide
Serum fructosamine
OGTT
24h urine

Full Information

First Posted
October 1, 2007
Last Updated
March 20, 2015
Sponsor
AstraZeneca
search

1. Study Identification

Unique Protocol Identification Number
NCT00538174
Brief Title
Phase I Multiple-Ascending Dose (Japan)
Acronym
MAD
Official Title
A Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Diabetic Japanese Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
November 2007 (undefined)
Primary Completion Date
May 2008 (Actual)
Study Completion Date
May 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) following once daily oral doses of 2.5, 10, and 20 mg of dapagliflozin in diabetic Japanese subjects administered for 14 days

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
36 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Arm 1
Arm Type
Experimental
Arm Description
2.5 mg
Arm Title
Arm 2
Arm Type
Experimental
Arm Description
10 mg
Arm Title
Arm 3
Arm Type
Experimental
Arm Description
20 mg
Arm Title
Arm 4
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Dapagliflozin
Intervention Description
Tablets, Oral, once daily up, to 14 days
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
Tablets, Oral, 0 mg, once daily, up to 14 days
Primary Outcome Measure Information:
Title
AEs, vital signs & physical exam
Time Frame
scr, Days -3, -1, 1, 2, 7, 12, 13, 14, 15, 21
Title
ECGs
Time Frame
scr, Days -1, 1, 2, 7, 12, 13, 14, 15, 21
Title
Clinical labs
Time Frame
scr, Days -1, 2, 7, 12, 14, 15, 21
Title
Urine safety markers
Time Frame
Days -1, 1, 14
Secondary Outcome Measure Information:
Title
24 hr PK blood & urine samples
Time Frame
Days 1 & 14
Title
Serum glucose, serum insulin, serum c-peptide
Time Frame
Days -1, 1, 14
Title
Serum fructosamine
Time Frame
Days -1, 14, 4 h
Title
OGTT
Time Frame
Days -2, 13 (after 10 h fast)
Title
24h urine
Time Frame
Days -1, 1 & 14 for glucose, creatinine & calcium

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Japanese male and female subjects Ages 20 to 70 years old Established diagnosis of T2DM BMI < 32 kg/m2 Fasting glucose ≤ 240 mg/dL, while on antidiabetic diet alone HbA1C 6.0 - 10.0% Exclusion Criteria: Symptomatic T2DM defined as polyuria and/or polydipsia within 2 months of enrollment History of diabetic ketoacidosis or hyperosmolar nonketotic syndrome History of incontinence or bladder dysfunction including nocturia
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bristol-Myers Squibb
Organizational Affiliation
Bristol-Myers K.K.
Official's Role
Study Director
Facility Information:
Facility Name
Local Institution
City
Suita
State/Province
Osaka
ZIP/Postal Code
5650853
Country
Japan

12. IPD Sharing Statement

Citations:
PubMed Identifier
21226818
Citation
Kasichayanula S, Chang M, Hasegawa M, Liu X, Yamahira N, LaCreta FP, Imai Y, Boulton DW. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab. 2011 Apr;13(4):357-65. doi: 10.1111/j.1463-1326.2011.01359.x.
Results Reference
result

Learn more about this trial

Phase I Multiple-Ascending Dose (Japan)

We'll reach out to this number within 24 hrs